Natick, Massachusetts • Clinical-Stage Oncology Biotech • Est. 2016
PIC Therapeutics
Rewriting how cancer is treated - at the moment a cell decides which proteins to build.
Rewriting how cancer is treated - at the moment a cell decides which proteins to build.
PIC Therapeutics builds small-molecule medicines that do something most cancer drugs do not: instead of blocking a single oncogene, they intervene at the step where many oncogenic signals converge - the point at which a cell translates its genetic instructions into protein. Based in Natick, Massachusetts, and founded in 2016 on the research of Harvard structural biologist Gerhard Wagner, the company is developing an allosteric modulator of eIF4E, a translation factor that resistant cancers lean on heavily.
The wager is straightforward to state and hard to execute. If you can selectively dial down the production of cancer-driving proteins while leaving healthy cells largely untouched, you may be able to disarm tumors that have learned to route around conventional therapies. That is the problem PIC is built to attack, starting with drug-resistant metastatic breast cancer.
PIC develops small molecules that modulate the Pre-Initiation Complex and eIF4E to shut off the production of oncogene proteins - targeting protein synthesis itself rather than a single mutation.
Its first beneficiaries are people with advanced, drug-resistant metastatic breast cancer, and the oncologists treating tumors that no longer respond to standard targeted therapy.
Block one oncogene and tumors reroute. By acting on a shared convergence point, PIC aims to trigger cancer-cell death while sparing normal cells - and stay ahead of escape routes.
Cancer's growth signals ultimately have to be turned into proteins. PIC's approach reads that assembly line and interrupts it selectively.
Multiple cancer pathways converge on the cell's translation machinery.
The Pre-Initiation Complex assembles around eIF4E to begin translating mRNA.
A small molecule alters eIF4E, selectively curbing oncogene protein output.
Cancer cells undergo apoptosis while normal cells are largely spared.
Most precision-oncology stories are about genetics - find the mutation, block the product. PIC works one layer over, on translation, the step between gene and protein. That framing is deliberate. eIF4E is widely agreed to be an important target in resistant cancer and notoriously hard to drug; PIC positions its lead program as first-in-mechanism, meaning it is attempting to do something that has not been done before rather than improve on a crowded field.
The nearest comparison in the public market is eFFECTOR Therapeutics, which also pursues selective translation regulation. But PIC's specific angle - allosteric modulation of eIF4E, rooted in decades of structural-biology work from Harvard's Gerhard Wagner and translation research associated with McGill's Nahum Sonenberg - gives it a distinct scientific lineage. In a landscape crowded with targeted breast-cancer developers, PIC's differentiation is the mechanism, not the indication.
PIC Therapeutics has developed a truly novel approach for eIF4E, an important target in resistant cancers.
- Gerry Brunk, Managing Director, Lumira VenturesA development-stage small-molecule allosteric modulator of eIF4E, advancing toward first-in-human, first-in-mechanism studies in advanced, drug-resistant breast cancer.
A discovery engine targeting the Pre-Initiation Complex and translation-initiation factors - a mechanism at the convergence of many oncogenic pathways.
Series A proceeds also support expansion of the approach into additional oncology indications beyond the lead breast-cancer program.
PIC runs the classic venture-backed biopharma playbook: raise equity, discover and develop proprietary small-molecule drug candidates, and create value by hitting scientific and clinical milestones. As a preclinical/clinical-stage developer it has no product revenue yet - value is realized through data, partnerships or licensing, and potentially acquisition, not sales.
Where it sits in the market is specific. It is a small, thesis-driven team operating at the frontier of translation-targeted oncology - a niche within precision cancer therapy that specialist life-science investors have backed with conviction. The company's expertise is concentrated: structural biology of translation initiation, medicinal chemistry around eIF4E, and the translational science to move an academic discovery into the clinic.
Series A led by OrbiMed with Lumira Ventures, Harrington Discovery Institute, Advent Life Sciences & Belinda Termeer.
CEO Katherine Bowdish, who joined in 2020, brings more than two decades of biopharmaceutical leadership - most recently at Sanofi - to a company built on Gerhard Wagner's structural-biology research.
This financing underscores the progress we've made to advance our lead program toward cancer therapies addressing cancer-driving oncogenes.
- Katherine Bowdish, President & CEO, PIC TherapeuticsWe are excited to partner with PIC Therapeutics as they build a differentiated targeted oncology company.
- Tal Zaks, OrbiMedEstablished in Natick, Massachusetts, building on Gerhard Wagner's Harvard research into translation initiation factors.
Raises $5 million to advance eIF4E-selective small molecules and appoints Katherine Bowdish as President & CEO.
Closes a $35 million Series A to push its allosteric eIF4E modulator toward first-in-human studies in drug-resistant breast cancer.
Official channels and coverage of PIC Therapeutics. Note: the company does not maintain public video demos or a YouTube channel; the links below are its verifiable web and press presence.